首页> 美国卫生研究院文献>ACS Omega >Inhibition of DNAMethylation at the MLH1 Promoter Region Using Pyrrole–ImidazolePolyamide
【2h】

Inhibition of DNAMethylation at the MLH1 Promoter Region Using Pyrrole–ImidazolePolyamide

机译:抑制DNA使用吡咯-咪唑在MLH1启动子区域进行甲基化聚酰胺纤维

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aberrant DNA methylation causes major epigenetic changes and has been implicated in cancer following the inactivation of tumor suppressor genes by hypermethylation of promoter CpG islands. Although methylated DNA regions can be randomly demethylated by 5-azacytidine and 5-aza-2′-deoxycytidine, site-specific inhibition of DNA methylation, for example, in the promoter region of a specific gene, has yet to be technically achieved. Hairpin pyrrole (Py)–imidazole (Im) polyamides are small molecules that can be designed to recognize and bind to particular DNA sequences. In this study, we synthesized the hairpin polyamide MLH1_–16 (Py-Im-β-Im-Im-Py-γ-Im-Py-β-Im-Py-Py) to target a CpG site 16 bp upstream of the transcription start site of the human MLH1 gene. MLH1 is known to be frequently silenced by promoter hypermethylation, causing microsatellite instability and a hypermutation phenotype in cancer. We show that MLH1_–16 binds to the target site and that CpG methylation around the binding site is selectively inhibited in vitro. MLH1_non, which does not have a recognition site in the MLH1 promoter, neitherbinds to the sequence nor inhibits DNA methylation in the region.When MLH1_–16 was used to treat RKO human colorectal cancercells in a remethylating system involving the MLH1 promoter under hypoxic conditions (1% O2), methylationof the MLH1 promoter was inhibited in the regionsurrounding the compound binding site. Silencing of the MLH1 expression was also inhibited. Promoter methylation and silencingof MLH1 were not inhibited when MLH1_non was added.These results indicate that Py–Im polyamides can act as sequence-specificantagonists of CpG methylation in living cells.
机译:异常的DNA甲基化会引起重大的表观遗传学变化,并已通过启动子CpG岛的超甲基化使肿瘤抑制基因失活,从而导致癌症。虽然甲基化的DNA区域可以被5-氮杂胞苷和5-氮杂-2'-脱氧胞苷随机地去甲基化,但是例如在特定基因的启动子区域中,DNA甲基化的位点特异性抑制尚待技术上实现。发夹吡咯(Py)-咪唑(Im)聚酰胺是小分子,可以设计为识别并结合特定的DNA序列。在这项研究中,我们合成了发夹聚酰胺MLH1-16(Py-Im-β-Im-Im-Py-γ-Im-Py-β-Im-Py-Py),以转录上游16 bp处的CpG位点为目标MLH1基因的起始位点。已知MLH1经常被启动子的超甲基化沉默,从而导致癌症中的微卫星不稳定性和超突变表型。我们显示MLH1-16与目标位点结合,结合位点周围的CpG甲基化在体外被选择性抑制。 MLH1_non,在MLH1启动子中没有识别位点,也没有与该序列结合,也不抑制该区域的DNA甲基化。当MLH1_-16用于治疗RKO人大肠癌时缺氧条件下(1%O2)下涉及MLH1启动子的重甲基化系统中的细胞,甲基化区域中MLH1启动子的表达被抑制围绕化合物结合位点。 MLH1表达的沉默也受到抑制。促进甲基化和沉默添加MLH1_non不会抑制MLH1的数量。这些结果表明Py–Im聚酰胺可以作为序列特异性的活细胞中CpG甲基化的拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号